RARE Daily

FDA Approves First Treatment for Rare Autoimmune Kidney Disease

November 16, 2026

Rare Daily Staff

The U.S. Food and Drug Administration has approved Genentech’s Gazyva for primary membranous nephropathy, making it the first treatment specifically approved for the rare autoimmune kidney disease, which can lead to kidney failure.

The approval covers adults with primary membranous nephropathy who are at risk of disease progression. The treatment is intended to induce remission of proteinuria, or abnormally high protein levels in the urine, a sign of kidney damage.

Primary membranous nephropathy develops when the immune system mistakenly attacks the kidneys’ tiny filtering structures, allowing protein that normally stays in the blood to leak into the urine. Patients may experience swelling and fatigue, and the damage can become irreversible. Without treatment, up to 30 percent of patients develop kidney failure within 10 years.

Gazyva is an engineered antibody that targets certain B cells, immune cells that help drive the disease. It attaches to a protein called CD20 on the cells’ surface and helps destroy them, both directly and by recruiting other parts of the immune system. The drug is administered by intravenous infusion.

The FDA based its decision on a late-stage clinical trial involving 142 adults who were randomly assigned to receive Gazyva or tacrolimus, an immune-suppressing medicine. Both patients and researchers knew which treatment each participant received.

After two years, 36.1 percent of patients receiving Gazyva achieved complete remission of proteinuria, compared with 5.7 percent of those receiving tacrolimus. The difference was statistically significant, meeting the study’s main goal.

When researchers counted both complete and partial remission at two years, the rates were 50 percent for Gazyva and 12.9 percent for tacrolimus.

Reducing protein leakage is an important treatment goal because it can help preserve kidney function. Genentech did not report whether Gazyva reduced the number of patients who developed kidney failure during the study.

“People living with primary membranous nephropathy face the risk of progressive kidney damage and significant uncertainty about their health,” said Marc Hurlbert, CEO of the National Kidney Foundation. “The first FDA approval of a treatment specifically for this condition is a milestone, finally giving patients and clinicians more treatment options.”

Genentech said the trial revealed no new safety concerns beyond Gazyva’s known risks. The most common side effects among patients with membranous nephropathy were infusion-related reactions and upper respiratory tract infections.

The drug can nevertheless cause serious or fatal infections. Its safety information warns that patients receiving Gazyva may have a higher risk of severe infections than those receiving tacrolimus. Other serious risks include reactivation of hepatitis B, severe allergic reactions and a rare, potentially fatal brain infection.

Stay Connected

Sign up for updates straight to your inbox.

FacebookTwitterInstagramYoutube